The US Securities and Exchange Commission is probing Illumina’s $7.1 billion buyout of Grail, Illumina disclosed in a regulatory filing Thursday afternoon.
The DNA sequencing giant said that it was informed in July that the SEC staff was seeking documents and communications as part of the investigation, including “certain statements and disclosures concerning Grail, its products and its acquisition, and related to the conduct and compensation of certain members of Illumina and Grail management, among other things.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.